This double-blind, placebo-controlled crossover trial (n=24) conducted by Maastricht University explores the prosocial effects of MDMA, oxytocin, and their interaction.
The study aims to understand the neurobiological mechanisms underlying prosocial behaviour induced by MDMA.
Participants, aged 18 to 40 and with MDMA use experience, will receive MDMA, oxytocin, 5-HT1A receptor blocker, or placebos in a crossover design.
The primary outcome measures include empathy and social interaction tasks, with secondary measures assessing oxytocin concentrations and control tasks. Recruitment for this study was completed before February 2024.
The results of the trial can be found here.
Topic Healthy Subjects
Country Netherlands
Visit trial
Status
Completed
Results Published
Yes
Start date
14 June 2011
End date
01 January 2012
Phase
Not Applicable
Design
Blinded
Type
Interventional
Generation
First
Participants
24
Sex
All
Age
18- 40
Therapy
No
Trial Details
This trial, led by Universiteit Maastricht, investigates the prosocial effects of MDMA and oxytocin in a double-blind, placebo-controlled crossover study involving 24 participants. The aim is to understand the neurobiological basis of prosocial behaviour induced by MDMA. Participants, aged 18 to 40 with MDMA experience, receive different treatments in a crossover design, with outcomes measured through empathy and social interaction tasks, alongside oxytocin concentration assessments.NCT Number NL34859.068.10
Sponsors & Collaborators
Maastricht UniversityMaastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.